Osteopontin protects the islets and β-cells from interleukin-1 β-mediated cytotoxicity through negative feedback regulation of nitric oxide

Endocrinology

Volumn 148, Issue 2, 2007, Pages 575-584

  Arafat, Hwyda A ^a   Katakam, Anand K ^a   Chipitsyna, Galina ^a   Gong, Qiaoke ^a   Vancha, Ajith R ^a   Gabbeta, Jagadeesh ^a   Dafoe, Donald C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERLEUKIN 1BETA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OSTEOPONTIN;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; GENE EXPRESSION; IMMUNOBLOTTING; INSULIN RELEASE; MALE; NEGATIVE FEEDBACK; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CYTOTOXINS; FEEDBACK, BIOCHEMICAL; GENE EXPRESSION; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MALE; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OLIGOPEPTIDES; OSTEOPONTIN; PROMOTER REGIONS (GENETICS); RATS; RATS, WISTAR; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 33846449547     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0970     Document Type: Article

References (41)

1. Bretzel RG, Alejandro R, Hering BJ, van Suylichem PT, Ricordi C 1994 Clinical islet transplantation: guidelines for islet quality control. Transplant Proc 26:388-392
2. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV 2000 Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238
3. Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AM 2002 Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 1:2148-2157
4. Kaufman DB, Platt JL, Rabe FL, Dunn DL, Bach FH, Sutherland DE 1990 Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts. J Exp Med 172:291-302
5. Gysemans CA, Waer M, Valckx D, Laureys JM, Mihkalsky D, Bouillon R, Mathieu C 2000 Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-β mRNA in the grafts. Diabetes 49:1992-1997
6. Eizirik DL, Flodstrom M, Karlsen AE, Welsh N 1996 The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic β cells. Diabetologia 39:875-890
7. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M 1986 Cytotoxicity of human pI 7interleukin-1 for pancreatic islets of Langerhans. Science 232:1545-1547
8. Southern C, Schulster D, Green IC 1990 Inhibition of insulin secretion by interleukin-1β and tumour necrosis factor-α via an L-arginine-dependent nitric oxide generating mechanism. FEBS Lett 276:42-44
9. Thomas HE, Darwiche R, Corbett JA, Kay TW 2002 Interleukin-1 plus β-interferon-induced pancreatic β-cell dysfunction is mediated by β-cell nitric oxide production. Diabetes 51:311-316
10. Corbett JA, Sweetland MA, Wang JL, Lancaster Jr JR, McDaniel ML 1993 Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci USA 90:1731-1735
11. Eizirik DL, Pavlovic D 1997 Is there a role for nitric oxide in β-cell dysfunction and damage in IDDM? Diabet Metab Rev 13:293-307
12. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS 2001 Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107:1055-1061
13. Denhardt DT, Guo X 1993 Osteopontin: a protein with diverse functions. FASEB J 7:1475-1482
14. Patarca R, Saavedra RA, Cantor H 1993 Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 13:225-246
15. Arafat HA, Wein AJ, Chacko S 2002 Osteopontin gene expression and immunolocalization in the rabbit urinary tract. J Urol 167:746-752
16. Yu XQ, Fan JM, Nikolic-Paterson DJ, Yang N, Mu W, Pichler R, Johnson RJ, Atkins RC, Lan HY 1999 IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat. Am J Pathol 154:833-841
17. Attur, M G, Dave M N, Clancy RM, Patel IR, Abramson SB, Amin AR 2000 Functional genomic analysis in arthritis affected cartilage: yin-yang regulation of inflammatory mediators by integrins. J Immunol 164:2684-2691
18. Hwang SM, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD, Denhardt DT 1994 Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Bi Chem 269:711-715
19. Guo H, Cai CQ, Schroeder RA, Kuo PC 2001 Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J Immunol 166:1079-1086
20. Rollo EE, Laskin DL, Denhardt DT 1996 Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J Leukocyte Biol 60:397-404
21. Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW, Bing OHL, Colucci WS 1999 Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 33:663-670
22. Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA 1995 Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. J Biol Chem 270:28471-28478
23. Katakam AK, Chipitsyna G, Gong Q, Vancha AR, Gabbeta J, Arafat HA 2005 Streptozotocin (STZ) mediates acute upregulation of serum and pancreatic osteopontin (OPN): a novel islet-protective effect of OPN through inhibition of STZ-induced nitric oxide production. J Endocrinol 187:237-247
24. Hill DJ, Petrik J, Arany E, McDonald TJ, Delovitch TL 1999 Insulin-like growth factors prevent cytokine-mediated cell death in isolated islets of Langerhans from pre-diabetic non-obese diabetic mice. J Endocrinol 16:153-165
25. Darville MI, Eizirik DL 1998 Regulation by cytokines of the inducible nitric oxide synthase promoter in insulin-producing cells. Diabetologia 41:1101-1108
26. Darville MI, Ho YS, Eizirik DL 2000 NF-κB is required for cytokine-induced manganese superoxide dismutase expression in insulin-producing cells. Endocrinology 141:153-162
27. Takemoto M, Yokote K, Nishimura M, Shigematsu T, Hasegawa T, Kon S, Uede T, Matsumoto T, Saito Y, Mori S 2000 Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 3:624-628
28. Asaumi S, Takemoto M, Yokote K, Ridall AL, Butler WT, Fujimoto M, Kobayashi K, Kawamura H, Take A, Saito Y, Mori S 2003 Identification and characterization of high glucose and glucosamine responsive element in the rat osteopontin promoter. J Diabetes Complications 17:34-38
29. Mandrup-Poulsen T, Nerup J, Reimers JI, Pociot F, Andersen HU, Karlsen A, Bjerre U, Bergholdt R 1995 Cytokines and the endocrine system. I. The immunoendocrine network. Eur J Endocrinol 133:660-671
30. Dinarello CA 1998 Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16:457-499
31. Bossy-Wetzel E, Lipton SA 2003 Nitric oxide signaling regulates mitochondrial number and function. Cell Death Differ 10:757-760
32. Delaney CA, Tyrberg B, Bouwens L, Vaghef H, Hellman B, Eizirik DL 1996 Sensitivity of human pancreatic islets to peroxynitrite-induced cell dysfunction and death. FEBS Lett 394:300-306
33. Delaney CA, Eizirik DL 1996 Intracellular targets for nitric oxide toxicity to pancreatic β-cells. Braz J Med Biol Res 29:569-579
34. Baldwin AS 1996 The NF-κ-b and I-κ-b proteins - new discoveries and insights. Annu Rev Immunol 14:649-683
35. Saldeen J, Welsh N 1994 Interleukin-1β induced activation of NF-κB in insulin producing RINm5F cells is prevented by the protease inhibitor N α-p-tosyl-L-lysine chloromethylketone. Biochem Biophys Res Commun 203:149-155
36. Flodstrom M, Welsh N, Eizirik DL 1996 Cytokines activate the nuclear factor κB (NF-κB) and induce nitric oxide production in human pancreatic islets. FEBS Lett 385:4-6
37. Giannoukakis N, Rudert WA, Trucco M, Robbins PD 2000 Protection of human islets from the effects of interleukin-1β by adenoviral gene transfer of an IκB repressor. J Biol Chem 275:36509-36513
38. Albakri, QA, Stuehr DJ 1996 Intracellular assembly of inducible NO synthase is limited by nitric oxide mediated changes in heme insertion and availability. J Biol Chem 271:5414-5421
39. Park SK, Lin HL, Murphy S 1997 Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-κB binding to DNA. Biochem J 322:609-613
40. DelaTorre A, Schroeder R A, Punzalan C, Kuo PC 1999 Endotoxin mediated S-nitrosylation of p50 alters NF-κB dependent gene transcription in ANA-1 murine macrophages. J Immunol 162:4101-4108
41. Guo X, Zhang YP, Mitchell DA, Denhardt DT, Chambers A F 1995 Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol 15:476-487